Three bids within the budget have moved the tender for Kielce’s Molecular Research Centre to bid evaluation. The Świętokrzyskie Oncology Centre must now examine the offers before choosing a contractor.
The tender for the centre’s construction received three offers. PORR submitted the lowest, at PLN 98.17 million gross. A Wodpol-PBO Śląsk consortium offered PLN 103.36 million, while a Climamedic-Adamietz Warszawa consortium proposed PLN 137.31 million. All are within the contracting authority’s PLN 141.35 million budget. Nauka w Polsce reported that the hospital must examine and evaluate the bids before selecting a contractor.
The planned facility is intended to combine comprehensive cancer profiling, genetic engineering and experimental cell therapies with a manufacturing unit for advanced therapy medicinal products. The centre’s director, Professor Stanisław Góźdź, said it is designed to develop CAR-T therapies, in which a patient’s own lymphocytes are modified to recognise particular cancer cells.
This tender stage is not the same as treatment reaching patients. Professor Góźdź estimated that producing such therapies at the new centre could cost about PLN 500,000, compared with PLN 1.5 million to PLN 2 million for ready-made CAR-T products. That is the director’s estimate, not a current treatment price. No contractor has been selected or contracted, and construction is planned to take 24 months after a contract is signed.
From a procurement perspective, three bids within budget allow the hospital to proceed with evaluation. Whether the project delivers the planned treatment infrastructure will depend on contractor selection, construction and subsequent required procedures.
Sources
- Nauka w Polsce · Fundacja PAP — Źródło: Nauka w Polsce (Fundacja PAP) (https://naukawpolsce.pl/) · Source date: 2026-11-15
Independent editorial content. WUA is not affiliated with any political party. 2026-11-15